X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Nitric oxide-releasing compound
Therapeutic Area: Cardiology/Vascular Diseases Product Name: R-107
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Claritas Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement April 21, 2021
Details:
R-107 is a liquid, nitric oxide-releasing compound with issued and pending composition of matter and method of use patents in approximately 40 countries, including the U.S., Australia, Brazil, China, Europe, India, Japan, Russia and South Korea.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): NYX-PCSK9i
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 06, 2020
Details:
According to pre-clinical results, the cells showed an increase in LDL receptor levels and demonstrated equivalency to marketed monoclonal PCSK9 antibody drugs, evolocumab and alirocumab.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
